Unicycive Therapeutics Q4 EPS $(0.35) Misses $(0.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
Unicycive Therapeutics (UNCY) reported a Q4 EPS loss of $(0.35), missing the consensus estimate of $(0.17) by 105.88%. This represents a 31.37% improvement over the $(0.51) per share loss from the same period last year.
March 29, 2024 | 4:53 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Unicycive Therapeutics reported a larger than expected Q4 loss of $(0.35) per share, missing the $(0.17) estimate but showing improvement from last year's $(0.51) loss.
The reported earnings miss is likely to negatively impact investor sentiment in the short term, as the loss was significantly larger than expected. However, the improvement over the previous year's loss may provide some mitigating context.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100